As the GLP-1 weight-loss drug market continues to grow, consumers weary of needles now have two options in pill form instead. Eli Lilly, the makers of Zepbound, gained FDA approval for its drug orforglipron, sold under the brand name Foundayo, on April 1, 2026, following Novo Nordisk, which received approval for the Wegovy pill in December 2025. Unlike the injectable forms of the drugs…
Read the full article here
